VALEANT PHARMACEUTICALS INTL's ticker is and the CUSIP is 91911K952. A total of 7 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $1,159,000 | +60.1% | 67,000 | +2.1% | 0.04% | +780.0% |
| Q1 2017 | $724,000 | -70.8% | 65,600 | -61.6% | 0.01% | -54.5% |
| Q4 2016 | $2,483,000 | +39.5% | 171,000 | +135.9% | 0.01% | +22.2% |
| Q3 2016 | $1,780,000 | -76.2% | 72,500 | -1.6% | 0.01% | -75.0% |
| Q4 2015 | $7,492,000 | -81.0% | 73,700 | -66.6% | 0.04% | -77.9% |
| Q3 2015 | $39,386,000 | +0.3% | 220,800 | +24.9% | 0.16% | -7.4% |
| Q2 2015 | $39,276,000 | +1.8% | 176,800 | -9.0% | 0.18% | +1.1% |
| Q1 2015 | $38,572,000 | +353.7% | 194,200 | +226.9% | 0.17% | +411.8% |
| Q4 2014 | $8,501,000 | -23.6% | 59,400 | -30.0% | 0.03% | -26.1% |
| Q3 2014 | $11,126,000 | -28.0% | 84,800 | -30.8% | 0.05% | -34.3% |
| Q2 2014 | $15,462,000 | +82.4% | 122,600 | +90.7% | 0.07% | +94.4% |
| Q1 2014 | $8,477,000 | -5.0% | 64,300 | -15.4% | 0.04% | +12.5% |
| Q4 2013 | $8,922,000 | +2.8% | 76,000 | -8.7% | 0.03% | +6.7% |
| Q3 2013 | $8,680,000 | +0.6% | 83,200 | -17.0% | 0.03% | -6.2% |
| Q2 2013 | $8,625,000 | – | 100,200 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pentwater Capital Management LP | 3,770,300 | $75,934,000 | 1.01% |
| SIMPLEX TRADING, LLC | 8,247 | $6,549,000 | 0.44% |
| Thrax Management, LLC | 100,000 | $2,014,000 | 0.31% |
| GROUP ONE TRADING, L.P. | 994,600 | $20,031,000 | 0.24% |
| CMT Asset Management Ltd | 192,800 | $3,883,000 | 0.20% |
| Citadel Advisors | 1,838,900 | $37,035,000 | 0.04% |
| JPMORGAN CHASE & CO | 135,000 | $2,719,000 | 0.00% |